Martin Shkreli Warns of 80% Crash in aTyr Pharma Shares, Despite 'Strong Buy' Rating

Martin Shkreli, a controversial American investor, has revealed a short position against aTyr Pharma, citing concerns about the company's lead drug, efzofitimod. Shkreli argues that the drug's Phase 2 data is misleading and that its mechanism of action lacks scientific rationale. Despite this, Wall Street remains bullish on aTyr Pharma, with a consensus rating of "Strong Buy" and a mean target of $20, indicating potential upside of 300% from current levels.